Literature DB >> 25182154

Inhibition mechanism of Qingluo Tongbi Granule () on osteoclast differentiation induced by synovial fibroblast and monocytes co-culture in adjuvant-induced arthritic rats.

Tian-yang Liu1, Ling-ling Zhou, Cong Zhou, Zhang-pu Liu, Chen Chen, Zhe Feng, Xue-ping Zhou.   

Abstract

OBJECTIVE: To study the mechanism underlying the inhibitory effect of Qingluo Tongbi Granule (, QTG) on osteoclast differentiation in rheumatoid arthritis in rats.
METHODS: Fibroblast and monocyte co-culture were used to induce osteoclast differentiation in adjuvant-induced arthritic (AIA) rats. Serum containing QTG was prepared and added to the osteoclasts, and activation of the tumor necrosis factor receptor-associated factor 6/mitogen-activated protein kinase/nuclear factor of activated T cells, cytoplasmic1 (TRAF6/MAPK/NFATc1) pathways was examined.
RESULTS: The induced osteoclasts were multinucleated and stained positive for tartrate-resistant acid phosphatase (TRAP) staining. Serum containing QTG at 14.4, 7.2 or 3.6 g/kg inhibited the activation of TRAF6, extracellular regulated protein kinase (ERK)1/2, c-Jun N-terminal kinase (JNK) and p38 and decreased the percentage of cells with nuclear NFATc1 in a dose-dependent manner, the high and middle doses exhibited clear inhibitory activity (P<0.01 and P<0.05, respectively). After the addition of MAPK inhibitors, the NFATc1 expression showed no significant difference compared with the control group (P>0.05).
CONCLUSIONS: Serum containing QTG could generally inhibit the TRAF6/MAPK pathways and possibly inhibit the NFATc1 pathway. In addition, QTG may regulate other signaling pathways that are related to osteoclast differentiation and maturation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25182154     DOI: 10.1007/s11655-014-1839-x

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  13 in total

Review 1.  Osteoclastogenesis--current knowledge and future perspectives.

Authors:  M P Yavropoulou; J G Yovos
Journal:  J Musculoskelet Neuronal Interact       Date:  2008 Jul-Sep       Impact factor: 2.041

2.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.

Authors:  Hiroshi Takayanagi; Sunhwa Kim; Takako Koga; Hiroshi Nishina; Masashi Isshiki; Hiroki Yoshida; Akio Saiura; Miho Isobe; Taeko Yokochi; Jun-ichiro Inoue; Erwin F Wagner; Tak W Mak; Tatsuhiko Kodama; Tadatsugu Taniguchi
Journal:  Dev Cell       Date:  2002-12       Impact factor: 12.270

3.  Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.

Authors:  K Matsuzaki; N Udagawa; N Takahashi; K Yamaguchi; H Yasuda; N Shima; T Morinaga; Y Toyama; Y Yabe; K Higashio; T Suda
Journal:  Biochem Biophys Res Commun       Date:  1998-05-08       Impact factor: 3.575

Review 4.  Functions of nuclear factor kappaB in bone.

Authors:  Brendan F Boyce; Zhenqiang Yao; Lianping Xing
Journal:  Ann N Y Acad Sci       Date:  2010-03       Impact factor: 5.691

5.  IL-15 promotes osteoclastogenesis via the PLD pathway in rheumatoid arthritis.

Authors:  Mi Kyung Park; Yang-Mi Her; Mi La Cho; Hye-Joa Oh; Eun-Mi Park; Seung-Ki Kwok; Ji Hyeon Ju; Kyung Su Park; Do-Sik Min; Ho-Youn Kim; Sung-Hwan Park
Journal:  Immunol Lett       Date:  2011-05-19       Impact factor: 3.685

6.  The human osteoclast precursor circulates in the monocyte fraction.

Authors:  Y Fujikawa; J M Quinn; A Sabokbar; J O McGee; N A Athanasou
Journal:  Endocrinology       Date:  1996-09       Impact factor: 4.736

7.  Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways.

Authors:  Y H Zhang; A Heulsmann; M M Tondravi; A Mukherjee; Y Abu-Amer
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

8.  Osteoclast fusion and regulation by RANKL-dependent and independent factors.

Authors:  Lianping Xing; Yan Xiu; Brendan F Boyce
Journal:  World J Orthop       Date:  2012-12-18

Review 9.  Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.

Authors:  Anne-Priscille Trouvin; Vincent Goëb
Journal:  Clin Interv Aging       Date:  2010-11-19       Impact factor: 4.458

10.  Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis.

Authors:  Nacksung Kim; Yuho Kadono; Masamichi Takami; Junwon Lee; Seoung-Hoon Lee; Fumihiko Okada; Jung Ha Kim; Takashi Kobayashi; Paul R Odgren; Hiroyasu Nakano; Wen-Chen Yeh; Sun-Kyeong Lee; Joseph A Lorenzo; Yongwon Choi
Journal:  J Exp Med       Date:  2005-09-05       Impact factor: 14.307

View more
  3 in total

1.  Protection of catalpol against triptolide-induced hepatotoxicity by inhibiting excessive autophagy via the PERK-ATF4-CHOP pathway.

Authors:  Linluo Zhang; Changqing Li; Ling Fu; Zhichao Yu; Gengrui Xu; Jie Zhou; Meiyu Shen; Zhe Feng; Huaxu Zhu; Tong Xie; Lingling Zhou; Xueping Zhou
Journal:  PeerJ       Date:  2022-01-05       Impact factor: 2.984

2.  Qingluo Tongbi Formula Alleviates Hepatotoxicity Induced by Tripterygium wilfordii Hook. F. by Regulating Excessive Mitophagy Through the PERK-ATF4 Pathway.

Authors:  Linluo Zhang; Jie Zhou; Zhe Feng; Baoping Jiang; Changqing Li; Lingling Zhou; Xueping Zhou
Journal:  Front Pharmacol       Date:  2022-07-07       Impact factor: 5.988

3.  Network Pharmacology-Based Prediction and Verification of Qingluo Tongbi Formula to Reduce Liver Toxicity of Tripterygium wilfordii via UGT2B7 in Endoplasmic Reticulum.

Authors:  Ming Li; Jing Wang; Ling Fu; Yan Lu; Jianya Xu; Lingling Zhou; Huaxu Zhu; Liang Fang; Zhe Feng; Tong Xie; Xueping Zhou
Journal:  Med Sci Monit       Date:  2020-02-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.